Eloxx Pharmaceuticals (ELOX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Eloxx Pharmaceuticals (ELOX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $88M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Eloxx Pharmaceuticals's market cap?
Eloxx Pharmaceuticals (ELOX) has a market capitalization of approximately $88M, trading at
How profitable is Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Eloxx Pharmaceuticals pay a dividend?
Eloxx Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Eloxx Pharmaceuticals financially healthy?
Eloxx Pharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 0.48x, with a market beta of -24.60. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Eloxx Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Eloxx Pharmaceuticals (ELOX) the key facts are: market cap $88M, 52-week range 8.2-17.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Eloxx Pharmaceuticals's full fundamentals live
Get Eloxx Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.